Abstract
In this thesis, complement activation in COVID-19 was described and the effect of targeting complement factor C5a with the monoclonal antibody vilobelimab in severely and critically ill COVID-19 patients. The aim was to determine the effect of vilobelimab on mortality and safety in critically ill COVID-19 patients, to assess its effects on biomarkers of inflammation and coagulation in severely
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 31 May 2024 |
Publication status | Published - 2024 |